Cas:1890450-06-2 1-(1,1-difluoro-2-methylpropyl)-4-methyl-Benzene manufacturer & supplier

Chemical Name:1-(1,1-difluoro-2-methylpropyl)-4-methyl-Benzene

CAS.NO:1890450-06-2

Synonyms:1-(1,1-difluoro-2-methylpropyl)-4-methyl-Benzene

Molecular Formula:C₁₁H₁₄F₂

Molecular Weight:184.2256664

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:

Exact Mass:

LogP:

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 1-(1,1-difluoro-2-methylpropyl)-4-methyl-Benzene chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-(1,1-difluoro-2-methylpropyl)-4-methyl-Benzene physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-(1,1-difluoro-2-methylpropyl)-4-methyl-Benzene Use and application,1-(1,1-difluoro-2-methylpropyl)-4-methyl-Benzene technical grade,usp/ep/jp grade.

Related News: f you’ve traveled in or transited through mainland China, you won’t be allowed into New Zealand unless you’re a New Zealand national. 1-(1,1-difluoro-2-methylpropyl)-4-methyl-Benzene manufacturer Aduhelm, however, is in a different league in terms of the number of potential patients and cost to the healthcare system. 1-(1,1-difluoro-2-methylpropyl)-4-methyl-Benzene supplier Characteristic APIs represented by cardiovascular, antiviral, antitumor and other categories are targeted at generic APIs with patent expiring original research drugs, which have high scientific and technological content and rich profits. They have developed in China in the past decade. The more active API segment has contributed to the rise of Huahai Pharmaceutical, Chuangnuo Pharmaceutical, and Jiangbei Pharmaceutical. 1-(1,1-difluoro-2-methylpropyl)-4-methyl-Benzene vendor Characteristic APIs represented by cardiovascular, antiviral, antitumor and other categories are targeted at generic APIs with patent expiring original research drugs, which have high scientific and technological content and rich profits. They have developed in China in the past decade. The more active API segment has contributed to the rise of Huahai Pharmaceutical, Chuangnuo Pharmaceutical, and Jiangbei Pharmaceutical. 1-(1,1-difluoro-2-methylpropyl)-4-methyl-Benzene factory The cell product candidate is being developed under a collaboration with Memorial Sloan Kettering Cancer Center (MSK) led by Michel Sadelain, MD, PhD.